News ReleaseOridion Shareholders Approve All Motions by the Board of Directors at the Annual General Meeting 2011Jerusalem/Needham – June 15, 2011 – At the Annual General Meeting of Oridion Systems Ltd. (SIX Swiss Exchange: ORIDN), the shareholders approved all motions submitted by the Board of Directors with the required majority. A total of 2,728,360 ordinary shares were represented either by proxies or by shareholders personally attending the Meeting.

At the Annual General Meeting held on June 14, 2011, shareholders have taken note of the business results of the Company for the year ended December 31, 2010, and voted with the required majority in favor of all the resolutions proposed by the Board of Directors. Shareholders approved the following agenda items:

1. The amendment of Articles 36, 37 and 65 of the Articles of Association as proposed by the Board of Directors.

2. The re-election of Ms. Karen Sarid to serve as an Outside Director on the Board of

Directors for a period of three years until the AGM in 2014.

3. The grant to Ms. Sarid of an option to purchase 11,000 ordinary shares of the

Company.

4. The election of Professor Asher Tal to serve as a Director on the Board of Directors for two years until the AGM in 2013.

5. The grant to Professor Tal of an option to purchase 7,333 ordinary shares of the

Company.

6. The election of Dr. Fred Robertson to serve as a Director on the Board of Directors for three years until the AGM in 2014.

7. The grant to Dr. Robertson of an option to purchase 11,000 ordinary shares of the

Company.

8. The re-election of Dr. Morry Blumenfeld to serve as a Director on the Board of

Directors for three years until the AGM in 2014.

9. The grant to Dr. Blumenfeld of an option to purchase 11,000 ordinary shares of the

Company.

10. The form of Indemnification and Exemption Agreement to be entered by the

Company and its Directors and Officers, and the entrance by the Company into the

Indemnification Agreement with each of the Company’s Directors and Officers.

11. The renewal of Directors’ and Officers’ liability insurance policies. As proposed by the Board of Directors, the annual premium to be paid by the Company shall not exceed US$ 100,000, and until otherwise resolved by the appropriate organs of the Company, the aggregate coverage amounts of the D&O Insurance policy will not exceed US$ 30 million for all Directors and Officers.

12. The grant to Mr. Alan Adler, Chief Executive Officer and Chairman of the Board of Directors of the Company, of the annual bonus for the year 2010 in the amount of US$ 150,000.

13. The re-appointment of Kost Forer Gabbay & Kasierer, a member of Ernst & Young

International, as the Company’s independent public accountants for fiscal year 2011

and until the next Annual General Meeting. The Board of Directors was also authorized to fix the compensation of the auditors.

For further information please contact

Alan Adler, Chairman and Chief Executive Officer

Walter Tabachnik, Chief Financial Officer

Elena Gerberg, Investor Relations

e-mail investor@oridion.com website http://www.oridion.com phone +972 2 589 9159

address Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel

Upcoming events

August 29, 2011 Results 2nd Quarter / First Six Months 2011

November 14, 2011 Results 3rd Quarter / First Nine Months 2011

About Oridion

Oridion Systems Ltd. (www.oridion.com) is a global medical device company specializing in

patient safety monitoring. The Company operates through wholly owned subsidiaries in Israel and the United States.

Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient’s breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport,

alternate care and other settings where patients’ ventilation may be compromised and at risk.

Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward- looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology.

2